Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone.
Fawzi ThomasOnome Thomas AbiriJoyce M KallonDesmond Maada KangbaiThomas Ansumus ContehSally-Mattu ContehEdna G SamuelsOlufunsho AwodelePublished in: Drug, healthcare and patient safety (2024)
While the nOPV2 is relatively new, the majority of AEFI were not serious, and most serious cases were not causally linked to the vaccine. Participants exhibited variations in experience and awareness of AEFI reporting.
Keyphrases